Vietnam Plasma Fractionation Market by Product (Albumin, Immunoglobulins, Coagulation Factor VIII, and Coagulation Factor IX), Application (Neurology, Hematology, Immunology, Critical Care, and Others), and End User (Hospitals and Research Laboratories): Opportunity Analysis and Industry Forecast, 2020–2027
The Vietnam plasma fractionation market was valued at $56.62 million in 2019, and is expected to reach $79.03 million by 2027, registering a CAGR of 5.3% from 2020 to 2027. Blood is made up of solid components such as platelets, red blood cells, white blood cells, and a liquid component called plasma. Plasma is a straw-colored fluid, comprising 90% water and 10% dissolved gases, proteins, nutrients, ions, and waste materials. It contains a wide variety of proteins that can be isolated on the basis of their solubility characteristics particular to each protein at specific conditions of ethanol concentration, pH, temperature, ionic strength, and protein concentration. This enables extraction of these proteins through sequential precipitation allowing the isolation of certain proteins by centrifugation, filtration, and chromatography. Plasma fractionation is extensively used for manufacturing immunoglobulins and albumin along with several protein derivatives such as thrombin, protein C, factor IX, and factor VIII as key intermediates. These plasma derivatives have numerous applications in the fields of hematology, immune disorders, infectious diseases, shock, burns, restoring blood volume in trauma as well as rare chronic conditions. For instance, clotting factors in blood plasma are used for treating coagulation disorders such as disseminated intravascular coagulation or hemophilia. In critical care conditions, plasma is often prescribed to prevent and stop bleeding. Moreover, some of these derivatives are declared as essential medicines by WHO as there are no substitutes available in the market, thus creating various opportunities for the manufacturers.
Vietnam, on the other hand, is a potentially large healthcare market wherein the presence of public sector is overpowering the private sector, comprising of more than 85% of the hospitals and commune health stations across the country. As per World Bank Group, Vietnam is considered as a middle-income country with a healthcare expenditure of 5.53% of its GDP. To succeed as a middle-income country, the Vietnamese government is currently focusing on building core public health capacities in workforce development, diseases surveillance, emergency management, laboratory systems, and others for prevention and control of diseases. In addition, based on the current demographic trends in Vietnam, it is projected to become an aged society by 2035. Thus, this estimated change in demographics is anticipated to increase the onset of different diseases among the Vietnamese population in the coming future thereby resulting in surged demand for novel and innovative disease management approaches. Moreover, owing to the long-lasting effect of the herbicides used in Second Indochina War (Vietnam War), the population is already bearing some major illnesses, correspondingly having a similar impact on the future generations in the country.
According to the data published by U.S. Department of Veterans Affairs in 2020, some of these illnesses include chronic B-cell leukemia, Hodgkin’s disease, multiple myeloma, Non-Hodgkin’s lymphoma, respiratory cancers, Chloracne, and diabetes mellitus type 2. Considering the current unmet medical needs within the country, the demand for the plasma products is expected to increase, justifying the ever-increasing incidences of immunological disorders, hemophilia, metabolic, and neurological disorders. Therefore, the country provides lucrative opportunities to the domestic pharmaceutical companies for setting up their plasma fractionation plants to meet the population demand. Considering the country’s need to work towards self-sufficiency in plasma fractionated products, in 2015, a local firm “An Phat Pharmaceutical and Medical Equipment JSC” proposed and received a license to develop Vietnam’s 1st plasma fractionation factory. The plant was scheduled to start the production of albumin, FVIII, prothrombin, IVIG, and other plasma derivatives from 2018. However, considering the unmet Good Manufacturing Practice (GMP) standards, the production discontinued. Later, in 2019, the blood bank in “Ho Chi Minh City Blood Transfusion Hospital” was declared to meet the GMP requirements as per European standards for treatment process of plasma. Currently, Vietnam does not have their own plasma manufacturing plant, it imports the plasma fractionated products namely the coagulation factors VIII, factor IX, and albumin, and gamma globulin products from developed countries. Thus, the blood bank provides an opportunity for Vietnam to manufacture their own plasma products and exchange it overseas.
The pre-existing medical conditions in the Vietnamese population, owing to the side effects of the Second Indochina War coupled with aging population is anticipated to drive the growth of the Vietnam plasma fractionation market. In addition, unavailability of the substitutes for plasma fractionated products is expected to drive the market growth in Vietnam, since these products cannot be replaced owing to their histocompatibility, post-translational modifications, and absence of recombinant approaches for replication of these proteins. On the contrary, stringent regulations, both in terms of higher quality standards of the products and integrated logistics to source and collect the blood plasma and timely delivery to clinics, hospitals, and pharmacies are the anticipated factors to hinder the market growth. However, the unmet medical needs of the Vietnamese population are possibly expected to provide profitable opportunities for the plasma fractionation manufacturers to expand their geographical reach.
The Vietnam plasma fractionation market is segmented on the basis of product, application, and end user. By product, the market is classified into albumin, immunoglobulins, coagulation factor VIII, and Coagulation factor IX. Under immunoglobulin segment, the Vietnam plasma fractionation market is further bifurcated in to intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG). By application, the market is categorized into neurology, hematology, immunology, critical care, and others. By end user, the Vietnam plasma fractionation market is bifurcated into hospitals and clinical research laboratories.
KEY BENEFITS FOR STAKEHOLDERS
Vietnam, on the other hand, is a potentially large healthcare market wherein the presence of public sector is overpowering the private sector, comprising of more than 85% of the hospitals and commune health stations across the country. As per World Bank Group, Vietnam is considered as a middle-income country with a healthcare expenditure of 5.53% of its GDP. To succeed as a middle-income country, the Vietnamese government is currently focusing on building core public health capacities in workforce development, diseases surveillance, emergency management, laboratory systems, and others for prevention and control of diseases. In addition, based on the current demographic trends in Vietnam, it is projected to become an aged society by 2035. Thus, this estimated change in demographics is anticipated to increase the onset of different diseases among the Vietnamese population in the coming future thereby resulting in surged demand for novel and innovative disease management approaches. Moreover, owing to the long-lasting effect of the herbicides used in Second Indochina War (Vietnam War), the population is already bearing some major illnesses, correspondingly having a similar impact on the future generations in the country.
According to the data published by U.S. Department of Veterans Affairs in 2020, some of these illnesses include chronic B-cell leukemia, Hodgkin’s disease, multiple myeloma, Non-Hodgkin’s lymphoma, respiratory cancers, Chloracne, and diabetes mellitus type 2. Considering the current unmet medical needs within the country, the demand for the plasma products is expected to increase, justifying the ever-increasing incidences of immunological disorders, hemophilia, metabolic, and neurological disorders. Therefore, the country provides lucrative opportunities to the domestic pharmaceutical companies for setting up their plasma fractionation plants to meet the population demand. Considering the country’s need to work towards self-sufficiency in plasma fractionated products, in 2015, a local firm “An Phat Pharmaceutical and Medical Equipment JSC” proposed and received a license to develop Vietnam’s 1st plasma fractionation factory. The plant was scheduled to start the production of albumin, FVIII, prothrombin, IVIG, and other plasma derivatives from 2018. However, considering the unmet Good Manufacturing Practice (GMP) standards, the production discontinued. Later, in 2019, the blood bank in “Ho Chi Minh City Blood Transfusion Hospital” was declared to meet the GMP requirements as per European standards for treatment process of plasma. Currently, Vietnam does not have their own plasma manufacturing plant, it imports the plasma fractionated products namely the coagulation factors VIII, factor IX, and albumin, and gamma globulin products from developed countries. Thus, the blood bank provides an opportunity for Vietnam to manufacture their own plasma products and exchange it overseas.
The pre-existing medical conditions in the Vietnamese population, owing to the side effects of the Second Indochina War coupled with aging population is anticipated to drive the growth of the Vietnam plasma fractionation market. In addition, unavailability of the substitutes for plasma fractionated products is expected to drive the market growth in Vietnam, since these products cannot be replaced owing to their histocompatibility, post-translational modifications, and absence of recombinant approaches for replication of these proteins. On the contrary, stringent regulations, both in terms of higher quality standards of the products and integrated logistics to source and collect the blood plasma and timely delivery to clinics, hospitals, and pharmacies are the anticipated factors to hinder the market growth. However, the unmet medical needs of the Vietnamese population are possibly expected to provide profitable opportunities for the plasma fractionation manufacturers to expand their geographical reach.
The Vietnam plasma fractionation market is segmented on the basis of product, application, and end user. By product, the market is classified into albumin, immunoglobulins, coagulation factor VIII, and Coagulation factor IX. Under immunoglobulin segment, the Vietnam plasma fractionation market is further bifurcated in to intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG). By application, the market is categorized into neurology, hematology, immunology, critical care, and others. By end user, the Vietnam plasma fractionation market is bifurcated into hospitals and clinical research laboratories.
KEY BENEFITS FOR STAKEHOLDERS
- This report provides a detailed quantitative analysis of the current market trends and future estimations from 2020 to 2027, which assists to identify the prevailing market opportunities.
- An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
- A comprehensive analysis of the factors that drive and restrain the growth of the Vietnam plasma fractionation market is provided.
- An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
- By Product
- Albumin
- Immunoglobulins
- Subcutaneous Immunoglobulin (SCIG)
- Intravenous Immunoglobulin (IVIG)
- Coagulation Factor VIII
- Coagulation Factor IX
- By Application
- Neurology
- Hematology
- Immunology
- Critical Care
- Others
- By End User
- Hospitals
- Clinical Research Laboratories
- Baxter International Inc.
- Biotest AG
- Bio Products Laboratory Ltd.
- Getz Healthcare
- Grifols SA
- Kedrion Biopharma
- Octapharma
- Novo Nordisk
- Sanova Healthcare
- Sanquin Blood Supply Foundation
- Takeda Pharmaceutical Company Limited
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Market overview
2.1.1. Market segmentation
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Thereat of new entrants
3.3.4. Threat of substitutes
3.3.5. Intensity of competitive rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Pre-existing medical conditions in Vietnam
3.4.1.2. Unavailability of substitutes
3.4.2. Restraint
3.4.2.1. Stringent Regulations
3.4.3. Opportunity
3.4.3.1. Unmet needs of Vietnamese Population
3.5. COVID-19 Impact Analysis
CHAPTER 4: PLASMA FRACTIONATION MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Albumin
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.3. Immunoglobulins
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.2.1. Subcutaneous Immunoglobulin
4.3.2.1.1. Market size and forecast
4.3.2.2. Intravenous Immunoglobulin
4.3.2.2.1. Market size and forecast
4.4. Coagulation factor VIII
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast
4.5. Coagulation factor IX
4.5.1. Market size and forecast
CHAPTER 5: PLASMA FRACTIONATION MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Neurology
5.2.1. Market size and forecast
5.3. Hematology
5.3.1. Market size and forecast
5.4. Immunology
5.4.1. Market size and forecast
5.5. Critical care
5.5.1. Market size and forecast
5.6. Others
5.6.1. Market size and forecast
CHAPTER 6: PLASMA FRACTIONATION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast
6.3. Clinical research laboratories
6.3.1. Market size and forecast
CHAPTER 7: COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. BIOTEST AG
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. BIO PRODUCTS LABORATORY LTD.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.4. GETZ HEALTHCARE
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. GRIFOLS SA
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. KEDRION BIOPHARMA
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. OCTAPHARMA
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.8. NOVO NORDISK
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. SANOVA HEALTHCARE
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.10. SANQUIN BLOOD SUPPLY FOUNDATION
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.11. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.11.1. Company overview
7.11.2. Company snapshot
7.11.3. Operating business segments
7.11.4. Product portfolio
7.11.5. Business performance
7.11.6. Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Market overview
2.1.1. Market segmentation
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Thereat of new entrants
3.3.4. Threat of substitutes
3.3.5. Intensity of competitive rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Pre-existing medical conditions in Vietnam
3.4.1.2. Unavailability of substitutes
3.4.2. Restraint
3.4.2.1. Stringent Regulations
3.4.3. Opportunity
3.4.3.1. Unmet needs of Vietnamese Population
3.5. COVID-19 Impact Analysis
CHAPTER 4: PLASMA FRACTIONATION MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Albumin
4.2.1. Key market trends and growth opportunities
4.2.2. Market size and forecast
4.3. Immunoglobulins
4.3.1. Key market trends and growth opportunities
4.3.2. Market size and forecast
4.3.2.1. Subcutaneous Immunoglobulin
4.3.2.1.1. Market size and forecast
4.3.2.2. Intravenous Immunoglobulin
4.3.2.2.1. Market size and forecast
4.4. Coagulation factor VIII
4.4.1. Key market trends and growth opportunities
4.4.2. Market size and forecast
4.5. Coagulation factor IX
4.5.1. Market size and forecast
CHAPTER 5: PLASMA FRACTIONATION MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Neurology
5.2.1. Market size and forecast
5.3. Hematology
5.3.1. Market size and forecast
5.4. Immunology
5.4.1. Market size and forecast
5.5. Critical care
5.5.1. Market size and forecast
5.6. Others
5.6.1. Market size and forecast
CHAPTER 6: PLASMA FRACTIONATION MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Market size and forecast
6.3. Clinical research laboratories
6.3.1. Market size and forecast
CHAPTER 7: COMPANY PROFILES
7.1. BAXTER INTERNATIONAL INC.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.2. BIOTEST AG
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. BIO PRODUCTS LABORATORY LTD.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.4. GETZ HEALTHCARE
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.5. GRIFOLS SA
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. KEDRION BIOPHARMA
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. OCTAPHARMA
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.8. NOVO NORDISK
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. SANOVA HEALTHCARE
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.10. SANQUIN BLOOD SUPPLY FOUNDATION
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.11. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.11.1. Company overview
7.11.2. Company snapshot
7.11.3. Operating business segments
7.11.4. Product portfolio
7.11.5. Business performance
7.11.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. DISEASES RELATED TO AGENT ORANGE
TABLE 02. VIETNAM PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 03. VIETNAM PLASMA FRACTIONATION MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 04. VIETNAM PLASMA FRACTIONATION MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 05. BAXTER: COMPANY SNAPSHOT
TABLE 06. BAXTER: PRODUCT SEGMENTS
TABLE 07. BAXTER: PRODUCT PORTFOLIO
TABLE 08. BIOTEST AG: COMPANY SNAPSHOT
TABLE 09. BIOTEST AG: OPERATING SEGMENTS
TABLE 10. BIOTEST AG: PRODUCT PORTFOLIO
TABLE 11. BIO PRODUCTS LABORATORY LTD.: COMPANY SNAPSHOT
TABLE 12. BIO PRODUCTS LABORATORY LTD.: OPERATING SEGMENTS
TABLE 13. BIO PRODUCTS LABORATORY LTD.: PRODUCT PORTFOLIO
TABLE 14. GETZ HEALTHCARE: COMPANY SNAPSHOT
TABLE 15. GETZ HEALTHCARE: OPERATING SEGMENTS
TABLE 16. GETZ HEALTHCARE: PRODUCT PORTFOLIO
TABLE 17. GRIFOLS SA: COMPANY SNAPSHOT
TABLE 18. GRIFOLS SA: OPERATING SEGMENTS
TABLE 19. GRIFOLS SA: PRODUCT PORTFOLIO
TABLE 20. KEDRION: COMPANY SNAPSHOT
TABLE 21. KEDRION: OPERATING SEGMENTS
TABLE 22. KEDRION: PRODUCT PORTFOLIO
TABLE 23. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 24. OCTAPHARMA: OPERATING SEGMENTS
TABLE 25. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 26. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 27. NOVO NORDISK: OPERATING SEGMENTS
TABLE 28. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 29. SANOVA HEALTHCARE: COMPANY SNAPSHOT
TABLE 30. SANOVA HEALTHCARE: OPERATING SEGMENTS
TABLE 31. SANOVA HEALTHCARE: PRODUCT PORTFOLIO
TABLE 32. SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 33. SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
TABLE 34. SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 35. TAKEDA: COMPANY SNAPSHOT
TABLE 36. TAKEDA: PRODUCT PORTFOLIO
TABLE 01. DISEASES RELATED TO AGENT ORANGE
TABLE 02. VIETNAM PLASMA FRACTIONATION MARKET, BY PRODUCT, 2019–2027 ($MILLION)
TABLE 03. VIETNAM PLASMA FRACTIONATION MARKET, BY APPLICATION, 2019–2027 ($MILLION)
TABLE 04. VIETNAM PLASMA FRACTIONATION MARKET, BY END USER, 2019–2027 ($MILLION)
TABLE 05. BAXTER: COMPANY SNAPSHOT
TABLE 06. BAXTER: PRODUCT SEGMENTS
TABLE 07. BAXTER: PRODUCT PORTFOLIO
TABLE 08. BIOTEST AG: COMPANY SNAPSHOT
TABLE 09. BIOTEST AG: OPERATING SEGMENTS
TABLE 10. BIOTEST AG: PRODUCT PORTFOLIO
TABLE 11. BIO PRODUCTS LABORATORY LTD.: COMPANY SNAPSHOT
TABLE 12. BIO PRODUCTS LABORATORY LTD.: OPERATING SEGMENTS
TABLE 13. BIO PRODUCTS LABORATORY LTD.: PRODUCT PORTFOLIO
TABLE 14. GETZ HEALTHCARE: COMPANY SNAPSHOT
TABLE 15. GETZ HEALTHCARE: OPERATING SEGMENTS
TABLE 16. GETZ HEALTHCARE: PRODUCT PORTFOLIO
TABLE 17. GRIFOLS SA: COMPANY SNAPSHOT
TABLE 18. GRIFOLS SA: OPERATING SEGMENTS
TABLE 19. GRIFOLS SA: PRODUCT PORTFOLIO
TABLE 20. KEDRION: COMPANY SNAPSHOT
TABLE 21. KEDRION: OPERATING SEGMENTS
TABLE 22. KEDRION: PRODUCT PORTFOLIO
TABLE 23. OCTAPHARMA: COMPANY SNAPSHOT
TABLE 24. OCTAPHARMA: OPERATING SEGMENTS
TABLE 25. OCTAPHARMA: PRODUCT PORTFOLIO
TABLE 26. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 27. NOVO NORDISK: OPERATING SEGMENTS
TABLE 28. NOVO NORDISK: PRODUCT PORTFOLIO
TABLE 29. SANOVA HEALTHCARE: COMPANY SNAPSHOT
TABLE 30. SANOVA HEALTHCARE: OPERATING SEGMENTS
TABLE 31. SANOVA HEALTHCARE: PRODUCT PORTFOLIO
TABLE 32. SANQUIN BLOOD SUPPLY FOUNDATION: COMPANY SNAPSHOT
TABLE 33. SANQUIN BLOOD SUPPLY FOUNDATION: OPERATING SEGMENTS
TABLE 34. SANQUIN BLOOD SUPPLY FOUNDATION: PRODUCT PORTFOLIO
TABLE 35. TAKEDA: COMPANY SNAPSHOT
TABLE 36. TAKEDA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. VIETNAM PLASMA FRACTIONATION MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MODERATE BARGAINING POWER OF BUYERS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. MODERATE COMPETITIVE RIVALRY
FIGURE 08. PERCENTAGE OF AGING POPULATION IN VIETNAM (AGED 65 AND OVER) 2015–2018
FIGURE 09. BAXTER: NET SALES, 2017–2019 ($MILLION)
FIGURE 10. BAXTER: REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 11. BAXTER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 12. BIOTEST AG: NET SALES, 2017–2019 ($MILLION)
FIGURE 13. BIOTEST AG: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 14. BIOTEST AG: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 15. GRIFOLS SA: NET SALES, 2017–2019 ($MILLION)
FIGURE 16. GRIFOLS SA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 17. GRIFOLS SA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 18. KEDRION: NET SALES, 2017–2019 ($MILLION)
FIGURE 19. KEDRION: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 20. NOVO NORDISK: NET SALES, 2017–2019 ($MILLION)
FIGURE 21. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 22. NOVO NORDISK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 23. SANQUIN BLOOD SUPPLY FOUNDATION: NET SALES, 2017–2018 ($MILLION)
FIGURE 24. SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 26. TAKEDA: NET SALES, 2018–2020 ($MILLION),
FIGURE 27. TAKEDA: REVENUE SHARE, BY REGION, 2020 (%)
COMPANIES MENTIONED
Baxter International Inc., Biotest AG, Bio Products Laboratory Ltd., Getz Healthcare, Grifols SA, Kedrion Biopharma, Octapharma, Novo Nordisk, Sanova Healthcare, Sanquin blood supply foundation, and Takeda pharmaceutical company limited.
FIGURE 01. VIETNAM PLASMA FRACTIONATION MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. MODERATE BARGAINING POWER OF BUYERS
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. MODERATE COMPETITIVE RIVALRY
FIGURE 08. PERCENTAGE OF AGING POPULATION IN VIETNAM (AGED 65 AND OVER) 2015–2018
FIGURE 09. BAXTER: NET SALES, 2017–2019 ($MILLION)
FIGURE 10. BAXTER: REVENUE SHARE, BY SEGMENTS, 2019 (%)
FIGURE 11. BAXTER: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 12. BIOTEST AG: NET SALES, 2017–2019 ($MILLION)
FIGURE 13. BIOTEST AG: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 14. BIOTEST AG: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 15. GRIFOLS SA: NET SALES, 2017–2019 ($MILLION)
FIGURE 16. GRIFOLS SA: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 17. GRIFOLS SA: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 18. KEDRION: NET SALES, 2017–2019 ($MILLION)
FIGURE 19. KEDRION: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 20. NOVO NORDISK: NET SALES, 2017–2019 ($MILLION)
FIGURE 21. NOVO NORDISK: REVENUE SHARE, BY SEGMENT, 2019 (%)
FIGURE 22. NOVO NORDISK: REVENUE SHARE, BY REGION, 2019 (%)
FIGURE 23. SANQUIN BLOOD SUPPLY FOUNDATION: NET SALES, 2017–2018 ($MILLION)
FIGURE 24. SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY SEGMENT, 2018 (%)
FIGURE 25. SANQUIN BLOOD SUPPLY FOUNDATION: REVENUE SHARE, BY REGION, 2018 (%)
FIGURE 26. TAKEDA: NET SALES, 2018–2020 ($MILLION),
FIGURE 27. TAKEDA: REVENUE SHARE, BY REGION, 2020 (%)
COMPANIES MENTIONED
Baxter International Inc., Biotest AG, Bio Products Laboratory Ltd., Getz Healthcare, Grifols SA, Kedrion Biopharma, Octapharma, Novo Nordisk, Sanova Healthcare, Sanquin blood supply foundation, and Takeda pharmaceutical company limited.
